title: Quetiapine for the treatment of borderline personality disorder; an open-label study.
abstract: OBJECTIVE
  Only a few studies have commented on the use of atypical antipsychotics for the treatment of Borderline Personality Disorder (BPD) features, including affective dysregulation and aggression. We aimed at evaluating both efficacy and safety of quetiapine in a sample of consecutive BPD patients.
  
  
  METHODS
  29 BPD outpatients entered, and 23 completed, a 12 week, open-label, regime of quetiapine at an average daily dosage of 540 mg (range: 400-800 mg). Efficacy assessment psychometric instruments included: Hamilton Rating Scales for Depression (HAM-D); Brief Psychiatric Rating Scale (BPRS); Global Assessment of Functioning (GAF); Clinical Global Impression Scale (CGI); and Aggression Questionnaire (AQ).
  
  
  RESULTS
  Both completer and intent-to-treat analysis showed that most psychometric scales' scores exhibited a highly significant (HAM-D: p=.003; BPRS Hostility and Suspiciousness subscales; CGI; GAF; AQ: all at p=.000) improvement over time. Six patients dropped out early from treatment due to side effects; quetiapine was associated with two cases of transient thrombocytopenia.
  
  
  CONCLUSIONS
  Present findings would suggest that quetiapine may be effective for the treatment of a number of BPD features, including low mood and aggression. However, monitoring blood counts in patients receiving quetiapine seems to be justified.
authors.affiliation: I Clinica Psichiatrica, Policlinico Umberto I, Università La Sapienza di Roma, Viale Dell'Università, 30 - 00185, Rome, Italy.
authors.forename: Carmine
authors.initials: C
authors.lastname: Perrella
authors.forename: Dario
authors.initials: D
authors.lastname: Carrus
authors.forename: Emilia
authors.initials: E
authors.lastname: Costa
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Schifano
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects; D000374:Aggression / Q000523:psychology; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001883:Borderline Personality Disorder / Q000188:drug therapy* / Q000523:psychology; D003863:Depression / Q000523:psychology; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D000069348:Quetiapine Fumarate
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate